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ABSTRACT
Introduction Quantifying excess cause-speciﬁc
mortality among people with coeliac disease (CD)
compared with the general population accounting for
competing risks will allow accurate information to be
given on risk of death from speciﬁc causes.
Method We identiﬁed from the Clinical Practice
Research Datalink all patients with CD linked to Ofﬁce
for National Statistics between 1998 and 2012. We
selected controls by frequency matching from the
registered general practice population within 10-year age
bands. We calculated the adjusted cumulative incidence
(including adjustment for competing risks) and excess
cumulative incidence for different causes of death up to
10 years from diagnosis.
Results Of the 10 825 patients with CD, 773 died
within the study period. The overall mortality rate among
patients with CD was 128/10 000 person years
compared with 153/10 000 in controls (HR=0.94 95%
CI 0.84 to 1.01). We found no overall difference in the
cumulative incidence of respiratory disease, digestive
disease or cancer related death among cases and
controls. The adjusted cumulative incidence of death
from cardiovascular deaths was slightly lower compared
with those without CD diagnosis (CD 0.32% vs controls
0.41%) with a corresponding excess cumulative
incidence of −0.08% (95% CI −0.13 to −0.04).
However, patients with CD had 0.15% excess risk (95%
CI 0.03 to 0.27) of deaths from non-Hodgkin’s
lymphoma from the general population baseline risk.
Conclusions Overall, people with CD have no major
excess risk of cancer, digestive disease or respiratory
disease related or cardiovascular mortality compared
with the general population. These ﬁndings should be
reassuring to patients with CD and clinicians managing
their care.
INTRODUCTION
Coeliac disease (CD) affects 1% of the European
population yet only approximately 0.2% is clinic-
ally diagnosed.1 2 Numerous population based
studies have addressed the overall mortality risk of
people with either diagnosed CD or serologically
positive disease in the general population and
shown widely different ﬁndings. For instance, a
meta-analysis done on the subject reported esti-
mates ranging from a twofold increase in all-cause
mortality among patients with CD compared with
the general population to no increase in risk at all.3
Despite this work, there is a lack of contemporary
knowledge about the causes of death among clinic-
ally diagnosed patients which, if available, may be
useful in determining strategies to reduce some of
the associated mortality, if any such increases are
shown to exist.
Only a few studies4–10 have systematically ana-
lysed causes of death among people with CD com-
pared with the general population. For instance,
small UK based studies from cohorts predominantly
diagnosed in the 1980s and 1990s (with less than
200 deaths)6 9 10 have consistently reported slightly
higher cancer and digestive disease (International
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Signiﬁcance of this study
What is already known on this subject?
▸ Coeliac disease (CD) affects 1% of the
European population yet only approximately
0.2% are clinically diagnosed.
▸ There is a lack of contemporary knowledge
about the causes of death among clinically
diagnosed patients which may be useful in
determining strategies to reduce some of the
associated mortality.
▸ None of the previous studies on the subject
have adjusted their analysis for competing risk
which may lead to overestimation of associated
cause-speciﬁc mortality risks.
What are the new ﬁndings?
▸ By 10 years after diagnosis people with CD
have no major excess risk of cancer, digestive
disease or respiratory disease related, or
cardiovascular mortality compared with the
general population.
▸ Those with CD had a slightly lower cumulative
incidence of cardiovascular death following
diagnosis.
▸ Patients with CD had a 0.15% excess risk of
dying from non-Hodgkin’s lymphoma up to
10 years post diagnosis.
How might it impact on clinical practice in
the foreseeable future?
▸ Our study provides the most contemporary
estimates of the risk of cause-speciﬁc mortality
among patients with CD. Overall our results
should be reassuring to patients and
practitioners.
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Classiﬁcation of Diseases V.2010 (ICD-10); K00–K93) related
mortality but have found no statistically signiﬁcant increased
risk of respiratory disease related or cardiovascular mortality
compared with the general population. In contrast, Peters
et al7 using Swedish inpatient registry data (from 828 deaths in
patients diagnosed between 1965 and 1994) reported statistic-
ally signiﬁcant 1.4-fold, threefold and eightfold increased risks
of cardiovascular, respiratory disease and digestive disease
related mortality, respectively, compared with the control
population. Ludvigsson et al8 conducted the largest study on
the subject, also from Sweden, which analysed 3049 deaths of
patients diagnosed with CD between 1969 and 2008.
Although the study reported a 39% increased risk of all-cause
mortality among patients with CD compared with the general
population, and excess of 19%, 55% and 36% for cardiovascu-
lar, neoplasm and respiratory disease related deaths, respect-
ively, their absolute excess risk was low (0.6, 1.1 and 0.2 per
1000 person years, respectively). Furthermore they also failed
to assess whether diagnosis or causes of death had changed
over time as their study spanned over 40 years. It is note-
worthy that no previous study has adjusted their analysis for
competing events (ie, taken into account that patients may die
from causes other than those of interest). For instance, if
patients with CD are more likely to die from neoplasm, then
their risk of death from other causes will be lower which needs
to be taken into account. Not adequately adjusting for compet-
ing risks may lead to overestimation of cause-speciﬁc mortality
risks.
In addition, there may be different patterns of morbidity and
mortality among the general population and among people with
CD between countries in which studies are carried out.8 9
Finally, there is lack of evidence quantifying the absolute excess
risk of speciﬁc causes of death compared with the general popu-
lation. Clearly determining this latter quantity in different coun-
tries and healthcare settings is of clinical importance for the
purposes of informing patients and clinicians worldwide.
Therefore, in this study, using electronic health primary care
data linked to national mortality data in England, UK, we have
quantiﬁed the excess cause-speciﬁc mortality among people with
CD by 10 years of diagnosis compared with the general popula-
tion while accounting for competing risks.
METHODS
Data source
We used the Clinical Practice Research Datalink11 (CPRD)
which is a large longitudinal UK database of computerised
primary care (ie, general practice) records. The vast majority of
the UK population is registered with general practitioners,12
who are responsible for overseeing a patient’s medical care
which includes coordination of their healthcare from hospital or
other secondary care facilities. The CPRD is subjected to quality
checks and a practice’s data is only used when it is of high
enough quality for research.13 This is denoted by deﬁning an
up-to-standard (UTS) time period for each practice. For the
purpose of this study we used the 53% of CPRD practices for
which cause-speciﬁc mortality data was available from the
Ofﬁce for National Statistics (ONS) death register. The CPRD
data linked to ONS is available from 1998 onwards and covers
approximately 3% of the English population. As this linkage
only covers England, practices from Northern Ireland, Wales
and Scotland were excluded. This study was approved by the
Independent Scientiﬁc Advisory Committee of the CPRD
(protocol 12_106R).
Study population
We previously identiﬁed people with CD from the general prac-
tice data between 1990 and 2012.1 From this population we
then selected the subgroup who were registered with primary
care practices that had consented linking to the ONS death
registry between 1998 and 2012. The diagnosis of CD was
based on Read codes representing CD ( J690.00 CD; J690.13
Gluten enteropathy; J690z00 CD NOS; J690100 Acquired CD;
J690.14 Sprue-nontropical; J690000 Congenital CD). Patients
could have a diagnosis of CD and dermatitis herpetiformis
(DH) but not DH alone. Each patient was assigned a date of
diagnosis corresponding to the date of their ﬁrst record of CD.
Comparison group
Controls were selected from the general population who did
not have a diagnosis of CD. For the present study controls were
only included if they were registered to primary care practices
that had consented to linkage with ONS data (the same criteria
as for the cases in our study). We also excluded controls with
any record of gluten-free prescription or those with DH
without CD diagnosis. For this group a random date, ‘pseudo
diagnosis date’ was generated between their date of birth and
study end date. We then calculated the age at ‘pseudo diagnosis
date’ for controls and frequency matched them to cases’ age at
diagnosis in 10-year age bands at a ratio of 10 controls to 1
case.
Follow-up
An open cohort study design was used within which people
could enter and exit at different calendar times and ages. The
study start date was deﬁned as the latest of: the start of linked
data with ONS (1 April 1998), the date of patient registration
with the practice and the ‘UTS date’ of that practice. For the
purpose of this study, we included incidence and prevalent CD
cases as previously deﬁned.1 Incident CD cases were followed
up from the date of diagnosis rather than their entry date into
the database. To sample a comparable follow-up time in the
controls, we followed them up from the ‘pseudo diagnosis date’
rather than their entry date into the database. Failure to do this
introduces a bias into the comparison as controls are followed
up for a longer time from a younger age than cases. The study
end date was deﬁned as the earliest of: the last date for linked
primary care data (22 June 2012), the date of patient transfer
out from practice, the date of patient’s death or the last date of
data collection from that practice.
Cause of death
Information on the underlying cause of death was extracted
from the ONS death register which records and codes all deaths
occurring in England from the death certiﬁcates based on WHO
guidelines.14 These deﬁne causes of death by ICD-10 codes
with the main underlying cause established for each death using
standardised rules. For this study we analysed the underlying
cause of death by the most frequent ICD-10 chapter headings
of neoplasms (ICD chapters C and D), circulatory disease (ICD
chapter I: including cerebrovascular and ischaemic heart
disease), respiratory disease (ICD chapter J), digestive disease
(ICD chapter K) and the remaining less frequent chapter head-
ings grouped together in an ‘other causes’ category. Causes of
death prior to 2001 were coded using ICD-9 and were therefore
mapped onto the relevant ICD-10 chapter headings. For our
cases and controls, we also used the information on age (at diag-
nosis date), sex and socioeconomic status (SES, derived from a
Abdul Sultan A, et al. Gut 2015;64:1220–1226. doi:10.1136/gutjnl-2014-308285 1221
Coeliac disease
patient’s area of residence). Areas of residence within England
are ranked according to the Indices of Multiple Deprivation
which comprise of a number of indicators covering different
aspects of deprivation (housing, employment, income, access to
services, education and skills, crime, living environment). These
ranked scores are then split into quintiles for the purposes of
analysis.
Statistical analysis
Crude mortality rates
Initially we calculated crude mortality rates among those with
and without CD per 10 000 person years. These rates where
then stratiﬁed by the most frequent ICD-10 chapter headings.
We also analysed speciﬁc causes of death under each ICD-10
chapter heading where there were previously published associa-
tions with CD.9
Adjusted analysis
As previously stated when studying causes of death, the group
of survivors (those who do not die during a particular point in
time) might not be representative of the initial cohort as deaths
from other causes can select out those with relevant risk
factors.15 One method to adjust for this bias uses cumulative
incidence functions (CIFs) (ie, the predicted adjusted cumulative
risk of death) from a competing risks model that calculates the
probability of overall survival from all causes, combined with
the instantaneous hazard of death for each speciﬁc cause. We
calculated CIFs for each speciﬁc cause of death using the basic
survival functions and HRs from the adjusted Cox proportional
hazards model by 10 years from diagnosis of CD. These models
were adjusted for age, sex and SES. We calculated the absolute
excess risk for each speciﬁc cause of death by taking the differ-
ence between the CIFs of those with and without CD. The 95%
CIs were calculated by bootstrapping (50 iterations). We
repeated the above analysis only for those with an incident diag-
nosis of CD within the CPRD UTS period. Finally, for incident
CD cases we identiﬁed those who had CD symptoms recorded
in the year prior to diagnosis. We only included symptoms of
diarrhoea, anaemia and weight loss in this subanalysis, because
other associated symptoms of tiredness and abdominal pain/
bloating were less speciﬁc and susceptible to misclassiﬁcation.
The CIFs and excess risk were then stratiﬁed by those with and
without having symptoms recorded within a year before
diagnosis.
Sensitivity analysis
We increased the speciﬁcity of our case deﬁnition by repeating
our incidence analyses after restricting our case population to
those who in addition to one diagnostic code of CD had either;
a relevant prescription for a gluten-free product or a second
documented record of their disease.
Ethical statement
This study was approved by the Independent Scientiﬁc Advisory
Committee reference number=10_193R.
RESULTS
Study population
Our cohort consisted of 10 825 patients with CD frequency
matched on age to 107 096 people without CD, contributing
60 225 and 640 086 person years of follow-up times, respect-
ively. The median follow-up from the study start to end dates
was calculated to be 5 years (IQR=2–10 years). Table 1 presents
the basic demographic characteristics of people with and
without CD along with the number of deaths which occurred
under each ICD-10 chapter heading. For the purpose of this
study we grouped together chapter headings as ‘other causes’
for which we had less than 10 deaths per heading in our CD
group which also included the symptoms’ chapter. The most fre-
quent chapter heading under ‘other causes’ was ‘infection’ fol-
lowed by ‘dermatological’. Compared with those without CD,
our CD cases were more likely to be women, slightly older and
belonging to higher social class.
Crude mortality rate
Overall, there were 773 deaths among people with CD and
9810 in those without CD, giving overall mortality rates of 128
and 153 per 10 000 person years, respectively. These rates were
not statistically different after adjusting for age and sex
(HR=0.94 (95% CI 0.84 to 1.01)). Table 2 shows the mortality
rates stratiﬁed by ICD-10 chapter headings. Overall the rate of
death from neoplasm among those with CD compared with
Table 1 Basic characteristics of the study population
Characteristics
Without CD
N=107 096
With CD
N=10 825
No. Per cent No. Per cent
Cohort (n)
Deaths 9810 – 773 –
Person years 640 086 – 60 225 –
Median follow-up in
years (IQR)
4.7 (1.7–10.1) 4.6 (1.7–9.0)
Sex (n=patients)
Male 52 401 48.9 3779 34.9
Female 54 695 51.1 7046 65.1
Age in years* (n=patients)
<5 5074 4.7 373 3.4
5–17 8631 8.1 1012 9.3
18–29 14 698 13.7 1454 13.4
30–49 35 886 33.5 3599 33.2
50–69 31 093 29 3135 29
>69 11 714 10.9 1252 11.6
SES quintile (n=patients)
1 (least deprived) 24 644 23.2 2946 27.5
2 24 448 23 2592 24.2
3 20 628 19.4 2111 19.7
4 21 101 19.9 1830 17.1
5 (Most deprived) 15 452 14.5 1253 11.7
Cause of death (n=deaths)
Circulatory 3244 33.1 209 27
Neoplasm 2763 28.2 229 29.6
Respiratory 1214 12.4 103 13.3
Digestive 438 4.5 52 6.7
Neurological 257 2.6 21 2.7
Genitourinary 177 1.8 16 2.1
Endocrine 120 1.2 15 1.9
Psychiatric 247 2.5 15 1.7
External 211 2.1 13 1.7
Musculoskeletal 69 0.7 10 1.3
Other 344 3.5 27 3.5
Not coded 726 7.4 63 8.2
*Age at diagnosis or start of study follow-up for prevalent CD cases.
CD, coeliac disease; SES, socioeconomic status.
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those without CD was broadly similar (38 vs 43 per 10 000
person years). However, non-Hodgkin’s lymphoma was asso-
ciated with an absolute excess mortality rate of 3 per 10 000
person years compared with those without CD (absolute
rate=4.3 vs 1.4 per 10 000 person years). CD cases had a
slightly lower rate of dying from breast, respiratory and prostate
cancers (absolute rate=1.3, 6.5 and 0.17 per 10 000 person
years, respectively). Patients with CD also had an overall lower
rate of death from cardiovascular disease compared with our
control population (35 vs 51 per 10 000 person years), but had
higher risk of dying from digestive diseases (9 vs 7 per 10 000
person years).
Cumulative incidence function
The above crude comparisons were not adjusted for age or com-
peting risks. We therefore determined the CIF of death for the
most frequent causes of death by ICD-10 chapter heading after
accounting for competing events (table 3). While the median
follow-up for our study was around 5 years, patients could enter
and leave the follow-up to contribute their average of 5 years at
any point in the subsequent 10 years after CD diagnosis. This
open cohort method allowed us to calculate cumulative
incidence of death by 10 years after CD diagnosis. The cumula-
tive incidence of cardiovascular death by 10 years post diagnosis
was slightly lower for those with CD compared with controls
(3.35% vs 4.72%) which corresponded to an excess CI of
−1.38% (95% CI −1.91 to −0.85). We observed that those
between the ages of 60–79 years had around 3% lower risk of
cardiovascular deaths by 10 years after CD diagnosis. Similarly,
those over the age of 80 years had 3% lower risk of respiratory
disease related deaths whereas those under the age of 50 years
had a very slight excess risk (0.18%) of respiratory disease
related deaths.
After adjusting cumulative incidence for competing events,
sex, SES and age, the overall cumulative incidence of death
by 10 years was calculated to be 2% among those with CD
(ﬁgure 1). We observed that there were no statistically signiﬁcant
differences for the overall cancer, digestive disease or respiratory
disease related mortality among those with and without CD
(table 4). However, patients with CD had a slightly lower risk of
cardiovascular deaths (excess CI −0.08% 95% CI −0.13 to
−0.04). Within neoplasm, we found that the cumulative inci-
dence of deaths from non-Hodgkin’s lymphoma was higher for
our case population corresponding to an excess CI of 0.15%
Table 2 Mortality rates per 10 000 person years stratified by International Classification of Diseases V.2010 (ICD-10) headings
Cause of death
With CD Without CD
n Rate 95% CI n Rate 95% CI
Overall mortality 773 128 119 137 9810 153 150 156
Neoplasm overall 229 38.0 33.4 43.3 2763 43.2 41.6 44.8
Oesophagus/stomach 21 3.5 2.3 5.3 210 3.3 2.9 3.8
Colon 19 3.2 2.0 4.9 151 2.4 2.0 2.8
Pancreas 19 3.2 2.0 4.9 144 2.2 1.9 2.6
Digestive (other) 16 2.7 1.6 4.3 187 2.9 2.5 3.4
Respiratory 39 6.5 4.7 8.9 604 9.4 8.7 10.2
Skin/bone/breast 14 2.3 1.4 3.9 316 4.9 4.4 5.5
Prostrate 10 1.7 0.9 3.1 212 3.3 2.9 3.8
Non-Hodgkin’s lymphoma 26 4.3 2.9 6.3 90 1.4 1.1 1.7
Leukaemia 7 1.2 0.6 2.4 78 1.2 1.0 1.5
Other or benign 58 9.6 7.4 12.5 772 12.1 11.2 12.9
Cardiovascular overall 209 34.7 30.3 39.7 3244 50.7 49.0 52.5
IHD 72 12.0 9.5 15.1 1303 20.4 19.3 21.5
Heart-other 29 4.8 3.3 6.9 512 8.0 7.3 8.7
CVA 81 13.4 10.8 16.7 833 13.0 12.2 13.9
Other-circulatory 27 4.5 3.1 6.5 596 9.3 8.6 10.1
Respiratory overall 103 17.1 14.1 20.7 1214 19.0 17.9 20.1
Respiratory infection 37 6.1 4.5 8.5 439 6.9 6.2 7.5
Chronic airway disease 39 6.5 4.7 8.9 414 6.5 5.9 7.1
Respiratory-other 27 4.5 3.1 6.5 361 5.6 5.1 6.3
Digestive overall 52 8.6 6.6 11.3 438 6.8 6.2 7.5
Upper-GI 2 0.3 0.1 1.3 98 1.5 1.3 1.9
Lower-GI 17 2.8 1.8 4.5 188 2.9 2.5 3.4
Liver/gall bladder/pancreas 22 3.7 2.4 5.5 148 2.3 2.0 2.7
Digestive-other 11 1.8 1.0 3.3 4 0.1 0.0 0.2
Neurological 21 3.5 2.3 5.3 257 4.0 3.6 4.5
Genitourinary 16 2.7 1.6 4.3 177 2.8 2.4 3.2
Endocrine 15 2.5 1.5 4.1 120 1.9 1.6 2.2
Psychiatric 15 2.5 1.5 4.1 247 3.9 3.4 4.4
External 13 2.2 1.3 3.7 211 3.3 2.9 3.8
Other 37 6.1 4.5 8.5 413 6.5 5.9 7.1
Not coded 63 10.5 8.2 13.4 726 11.3 10.5 12.2
CD, coeliac disease; CVA, cerebrovascular accident; IHD, ischaemic heart disease.
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(95% CI 0.03 to 0.27). Our cumulative incidence up to
10 years remained fairly similar when we restricted our analysis
to only incidence cases and stratiﬁed by those with and without
symptoms recorded within a year before CD diagnosis (table 5).
Sensitivity analysis
Seventy-six per cent of our CD cases received a relevant prescrip-
tion for a gluten-free product and/or a second documented record
of their disease. We found that our overall and cause-speciﬁc mor-
tality rates remained unchanged when we applied our restrictive
case deﬁnition (see online supplementary table S1).
DISCUSSION
Main ﬁndings
We have calculated the excess cumulative incidence of death
following a diagnosis of CD compared with the general
Figure 1 Cumulative incidence by time after diagnosis, adjusting for
competing events, age and sex.
Table 3 Cumulative incidence function and excess risk by
10 years post coeliac disease (CD) diagnosis adjusting for competing
risk. The results are stratified by age at diagnosis
Cause of death
With
CD
Without
CD Excess 95% CI*
Cardiovascular overall
(years)
3.35 4.72 −1.38 −1.91 −0.85
≤50 0.38 0.31 0.07 −0.18 0.33
50–59 1.64 1.93 −0.28 −1.05 0.48
60–69 3.55 6.28 −2.73 −4.19 −1.27
70–79 13.14 16.63 −3.49 −6.35 −0.64
≥80 27.99 32.39 −4.40 −10.30 1.51
Respiratory overall (years) 1.55 1.70 −0.15 −0.52 0.21
≤50 0.25 0.07 0.18 0.00 0.35
50–59 0.61 0.57 0.05 −0.53 0.62
60–69 2.19 1.87 0.32 −0.78 1.42
70–79 6.76 6.47 0.29 −2.13 2.71
≥80 9.87 13.13 −3.26 −6.28 −0.25
Neoplasm overall (years) 3.78 4.09 −0.31 −0.87 0.26
≤50 0.88 0.61 0.27 −0.11 0.65
50–59 3.83 3.28 0.55 −0.58 1.68
60–69 7.59 8.04 −0.45 −2.41 1.51
70–79 11.61 12.05 −0.45 −3.25 2.36
≥80 10.31 12.52 −2.22 −6.01 1.57
Digestive overall (years) 0.85 0.65 0.20 −0.07 0.48
≤50 0.37 0.14 0.23 −0.03 0.48
50–59 0.94 0.44 0.50 0.00 0.99
60–69 1.55 0.83 0.73 −0.13 1.58
70–79 1.36 1.82 −0.47 −1.52 0.59
≥80 3.26 3.55 −0.29 −2.93 2.34
Others overall (years) 1.78 2.03 −0.25 −0.62 0.12
≤50 0.46 0.43 0.02 −0.22 0.27
50–59 0.93 0.74 0.20 −0.46 0.86
60–69 1.08 1.65 −0.57 −1.45 0.30
70–79 4.89 5.94 −1.06 −3.11 1.00
≥80 19.30 17.80 1.51 −3.53 6.54
Not coded overall 0.81 0.84 −0.03 −0.28 0.23
*Bootstrap 50 iterations.
Table 4 Cumulative incidence function by 10 years of diagnosis
adjusted for competing risk, age, socioeconomic status and gender
Cause of death
With
CD
Without
CD Excess 95% CI*
Cardiovascular 0.32 0.41 −0.08 −0.13 −0.04
Ischemic heart disease 0.15 0.26 −0.05 −0.10 −0.00
Respiratory 0.11 0.10 0.00 −0.02 0.03
Respiratory infection 0.16 0.20 −0.04 −0.09 0.01
Neoplasm 1.24 1.21 0.04 −0.10 0.18
Non-Hodgkin’s lymphoma 0.21 0.06 0.15 0.03 0.27
Digestive 0.24 0.16 0.07 −0.01 0.16
Others 0.27 0.29 −0.02 −0.07 0.04
Not coded 0.27 0.25 0.02 −0.07 0.10
*Bootstrap 50 iterations.
CD, coeliac disease.
Table 5 Cumulative incidence function (CIF) by 10 years of
diagnosis adjusted for competing risk, age, socioeconomic status
and gender
Cause of death
Deaths
n
CIF
with CD Excess* 95% CI†
Restricting to only incident cases (overall CD cases=4687)
Cardiovascular 72 0.27 −0.13 −0.19 −0.07
Respiratory 30 0.07 −0.02 −0.05 0.01
Neoplasm 86 1.12 −0.05 −0.33 0.22
Digestive 18 0.19 0.04 −0.04 0.13
Others 38 0.22 −0.06 −0.14 0.01
Not coded 27 0.30 0.04 −0.09 0.17
Restricting to symptomatic incident cases (overall CD cases=1895)
Cardiovascular 34 0.25 −0.16 −0.24 −0.07
Respiratory 16 0.08 −0.02 −0.06 0.01
Neoplasm 36 0.97 −0.20 −0.51 0.12
Digestive 7 0.15 0.00 −0.08 0.09
Others 15 0.17 −0.11 −0.19 −0.03
Not coded 13 0.29 0.04 −0.11 0.18
Restricting to non-symptomatic incident cases (overall CD cases=2792)
Cardiovascular 38 0.29 −0.11 −0.20 −0.01
Respiratory 14 0.07 −0.02 −0.07 0.03
Neoplasm 50 1.25 0.09 −0.30 0.47
Digestive 11 0.22 0.08 −0.05 0.20
Others 23 0.28 −0.01 −0.13 0.10
Not coded 14 0.30 0.04 −0.13 0.22
The results are restricted to the incident cases and stratified by whether or not
symptoms were recorded within a year before diagnosis.
*Excess risk compared with controls.
†Bootstrap 50 iterations.
CD, coeliac disease.
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population. We have done this in a large unselected cohort of
more than 10 000 patients with CD and assessed the underlying
cause while accounting for competing events. Our analysis
showed no overall excess risk of cancer, digestive disease or
respiratory disease related, or cardiovascular mortality after
adjusting for age and sex. In fact, those with CD had a slightly
lower cumulative incidence of cardiovascular death following
diagnosis. Finally, we observed that patients with CD had a
0.15% excess risk of dying from non-Hodgkin’s lymphoma up
to 10 years post diagnosis.
Strengths and limitations
Our study used information on more than 10 000 patients with
CD diagnosis to analyse excess cumulative incidence of cause-
speciﬁc deaths compared with those without CD in England.
The use of this contemporary, nationally representative primary
care data makes our study ﬁndings generalisable to patients with
clinically diagnosed CD in the UK and allows comparisons with
the only other similar data available on this subject, which
comes from Sweden.7 8 Furthermore, we had a large sample size
and prospective follow-up, and were able to adjust for compet-
ing events which allowed us to calculate accurate, unbiased and
more detailed cause-speciﬁc cumulative mortality rates than
most previous studies done on the subject.
A potential weakness of conducting epidemiological studies
using routinely collected data is the validity of the diagnostic
data for each patient. However, the diagnosis of CD has been
validated in these data with a positive predictive value ranging
between 81% and 100%.16 We found that our cause-speciﬁc
absolute mortality rates remained unchanged when we restricted
our analysis to CD cases who had either a gluten-free prescrip-
tion or more than one CD diagnostic code in their medical
records. Previous studies suggest that of the 1% of the general
population that have a positive serology for CD only about
0.2% are clinically diagnosed in the UK.1 17 18 Therefore it is
possible that there may be people with undiagnosed CD in our
comparison cohort and it may be argued that we failed to
observe excess cause-speciﬁc mortality because of the
undetected CD in our control population. We believe that the
impact of this limitation will however be minimal as a previous
study by our group19 found no difference in the overall and
cause-speciﬁc mortality among those with undetected CD com-
pared with the general population in England. We acknowledge
that our comparison group may include some patients with IBS.
However it is very unlikely that this would inﬂuence our esti-
mates given that there is no evidence that IBS is associated with
increased mortality risk. In our study we found that 6% of our
comparison group had a diagnosis of IBS,20 however, our mor-
tality data remained unaltered when we excluded those patients
from our analysis.
Cause of death information in our study was from the ONS
death register which uses standardised WHO guidelines to
extract information on cause of death from the death certiﬁ-
cates. It is important to note that death certiﬁcates may be
imprecise, yet they are the ofﬁcial legal requirement for ascer-
taining the cause of death. As a consequence, death certiﬁcates
are the only standard method to extract information on the
cause of death across such a large population as we have used.
For the purpose of this study we only used the underlying cause
of death information to avoid changes in the coding require-
ments over time.
Our study also lacked compliance data on a gluten-free diet
among those with CD. Corrao et al4 previously demonstrated
higher overall mortality among those who were less adherent to
a gluten-free diet compared with those who were more adher-
ent. However their study only included a selected group of
patents identiﬁed from hospital and therefore results may not be
generalisable. While our study is one of the largest to look at
the mortality among patients with celiac disease, our median
follow-up was only 5 years (IQR=1.7–10). Therefore we
acknowledge that we may not have been able to capture the
very long-term consequences of the disease.
Other studies
We have conducted the ﬁrst study which has looked at the
excess risk of cause-speciﬁc death among people with CD while
taking into account competing risks. Although there are no
other reports available that have carried out such an analysis our
overall and cause-speciﬁc mortality rates are in concordance
with the most contemporary evidence on the subject. For
instance, we found neoplasm to be the most common cause of
death among patients with CD followed by cardiovascular
disease which is broadly consistent with other population based
studies from the UK.6 9
Overall, we found no excess risk of neoplasm related mortal-
ity among patients with CD, a ﬁnding which contradicts the
conclusion of most previous studies.6–9 21 For instance, the
largest study by Ludvigsson et al8 reported a 55% relative
increased risk of neoplasm related deaths among patients with
CD compared with controls which is in line with other UK
based studies by Grainge et al9 and Solaymani-Dodaran et al.6
This may be due to the fact that the previous studies did not
adjust for the risk of dying from other causes or that the
Swedish data had a far greater proportion of children in it than
ours and the Lothian and Derby studies had cohorts which were
mainly diagnosed before the year 2000. The unadjusted esti-
mates handle death from other causes as censoring which
assumes that the risk of death for the people who die is the
same as for the people who did not die. In most scenarios this
does not make biological sense.22 Furthermore, not adequately
adjusting for competing risk of death can result in considerable
overestimation (depending on the duration of follow-up) of
cause-speciﬁc death rates which can give misleading results
when comparing the occurrence of an outcome of interest.
After adjusting for competing risks, we did identify a statistically
signiﬁcant excess risk of death from non-Hodgkin’s lymphoma
(<0.1%) which is consistent with other studies.4–7 9
We observed a slightly lower risk of cardiovascular deaths
among those with CD. This ﬁnding is supported by another
population based study by West et al23 who reported a lower
prevalence of hypertension and hypercholesterolaemia com-
pared with the general population using the same database. Our
study showed no statistically signiﬁcant excessive risk of non-
malignant digestive disease or respiratory disease related deaths
among patients with CD. In contrast, a previous study from
Sweden8 reported a 36% increased risk of respiratory disease
related mortality. Finally, Grainge et al9 reported a fourfold
increased risk of non-malignant digestive disease related deaths
among patients with CD. However their results were based on
few cases (n=10) giving a wide CI. Moreover, the likelihood of
detecting CD may increase during the investigation for other
digestive diseases, therefore the excess risk of digestive disease
related mortality observed in the previous study may be attribut-
able to more detailed investigations being carried out among
those patients, that is, an ascertainment bias phenomenon.
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Implications
Our study has demonstrated that patients with CD have no
major excessive risk of cancer, digestive disease or respiratory
disease related, or cardiovascular mortality compared with the
general population. There is an excess risk of dying of
non-Hodgkin’s lymphoma among patients with CD but the
excess cumulative risk is very small indeed. Overall our ﬁndings
are reassuring to patients with CD and clinicians managing their
care.
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